Nufarm has delivered a sharp FY26 recovery in underlying earnings and cash generation, with leverage falling to 2.0 times despite a 7% revenue decline. The statutory loss, no ordinary dividend and ongoing restructuring show the turnaround remains unfinished.
- Underlying EBITDA up 25% to A$378.3 million
- Underlying NPAT returns to A$19.9 million profit
- Net debt falls 9% to A$748.7 million
- No ordinary dividend declared for FY26
- FY27 guidance points to further EBITDA and cash-flow growth
Margin Recovery Comes Despite Lower Revenue
The result was driven less by selling more product than by selling a better mix and cutting costs. Underlying gross profit increased 4% to A$989.0 million, lifting the margin to 30.8% from 27.6%, while underlying sales, general and administrative costs fell 6%. Crop Protection revenue dropped 11%, yet its EBITDA declined only 1% to A$364.6 million and its margin expanded 1.3 percentage points. Nufarm had previously outlined the same A$50m savings program, which targets a A$50 million annualised run rate by the end of FY27.
Seed Technologies supplied the more dramatic improvement. Revenue climbed 34% to A$448.8 million and EBITDA increased to A$86.4 million from A$13.9 million, with Seeds revenue up 16% and Seeds EBITDA up 22% to A$81.8 million. Renewable Oils also moved to positive EBITDA of A$4.6 million, helped by improved Omega-3 pricing and the absence of the prior year’s inventory revaluation. Nufarm says Seeds remains a priority for investment, while Omega-3 funding will depend on defined commercial and financial milestones.
Cash Generation Eases Balance Sheet Pressure
Operating cash flow rose 45% to A$236.0 million, while cash flow before tax and financing costs improved by A$158 million year on year. Nufarm reduced net working capital 12% to A$777.8 million and cut net debt 9% to A$748.7 million. Capital expenditure also fell 35% to A$159.4 million as management reset spending after a period of heavier investment. The company refinanced A$160 million of standby liquidity commitments after year-end, extending their maturity to November 2028 and increasing the facility to A$180 million.
The stronger balance sheet has not yet translated into a dividend. Nufarm’s policy links distributions to free cash flow and a leverage range of 1.5 to 2.0 times, while also allowing for growth investment. The board therefore decided not to declare a final dividend. That leaves the ordinary shareholder focused on capital recovery and earnings execution, while Nufarm’s step-up securities continue to carry distributions, including a proposed annualised rate of 9.07% for the period to April 2027.
FY27 Targets Put Execution Under the Microscope
Nufarm says FY27 trading has started in line with expectations and forecasts continued EBITDA growth, including mid-teens growth in Seed Technologies and mid-single-digit growth in Crop Protection. It expects capital expenditure below A$200 million, underlying net financing costs of about A$100 million, an underlying tax rate of 40% to 45%, and leverage within the 1.5 to 2.0 times long-term range at year-end. The benefits of the strategy refresh are expected to be weighted towards the second half of FY27, with the full impact in FY28.
The recovery still carries operational baggage. Nufarm is closing its Kwinana and Alsip manufacturing plants, transitioning operational management at Wyke to px Group and continuing to rationalise products, while an ongoing regulatory investigation relates to the Laverton manufacturing incident. The company also reported a tragic fatality in Brazil during the year and reduced executive incentive outcomes after the board assessed the health and safety component at zero. The immediate question is whether the promised savings can arrive without another round of disruption, and whether a 2.0-times leverage ceiling will prove durable through the next seasonal cycle.
Bottom Line?
Nufarm has bought itself financial breathing room, but FY27 must prove that margin gains and cost savings can outlast the restructuring charge.
Questions in the middle?
- Can Nufarm deliver the A$50 million annualised savings run rate by the end of FY27 without further manufacturing disruption?
- Will Seed Technologies sustain its sharp earnings growth as investment increases and Omega-3 funding remains milestone-led?
- When can leverage and free cash flow support the return of ordinary dividends to shareholders?